Jose D. Sollano

ORCID: 0000-0003-3227-1983
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Liver Disease and Transplantation
  • Gastric Cancer Management and Outcomes
  • Helicobacter pylori-related gastroenterology studies
  • Inflammatory Bowel Disease
  • Eosinophilic Esophagitis
  • Microscopic Colitis
  • Colorectal Cancer Screening and Detection
  • Gastroesophageal reflux and treatments
  • Drug-Induced Hepatotoxicity and Protection
  • Diagnosis and treatment of tuberculosis
  • Organ Transplantation Techniques and Outcomes
  • Genetic factors in colorectal cancer
  • Hepatitis Viruses Studies and Epidemiology
  • Esophageal and GI Pathology
  • Esophageal Cancer Research and Treatment
  • Liver Diseases and Immunity
  • Alcohol Consumption and Health Effects
  • Gastrointestinal Bleeding Diagnosis and Treatment
  • Mycobacterium research and diagnosis
  • Pancreatitis Pathology and Treatment
  • Tuberculosis Research and Epidemiology
  • Pancreatic and Hepatic Oncology Research

University of Santo Tomas
2016-2025

Cardinal Health (Australia)
2023

University of Santo Tomas Hospital
2006-2020

Institute of Liver and Biliary Sciences
2018-2019

Pfizer (United States)
2019

World Allergy Organization
2016

University of Asia and the Pacific
2011

Govind Ballabh Pant Hospital
2006-2008

Bausch Health (United States)
2008

University of Delhi
2006-2008

Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding natural history HBV potential for therapy resultant disease is continuously improving. New data become available since previous APASL guidelines management were published 2012. The objective this manuscript to update recommendations optimal infection. 2015 developed by a panel Asian experts chosen APASL. clinical practice are based on evidence...

10.1007/s12072-015-9675-4 article EN cc-by Hepatology International 2015-11-13

Colorectal cancer (CRC) is rapidly increasing in Asia, but screening guidelines are lacking. Through reviewing the literature and regional data, using modified Delphi process, Asia Pacific Working Group on Cancer international experts launch consensus recommendations aiming to improve awareness of healthcare providers changing epidemiology tests available. The incidence, anatomical distribution mortality CRC among Asian populations not different compared with Western countries. There a trend...

10.1136/gut.2007.146316 article EN Gut 2008-07-15

Abstract Background and Aim: Gastric cancer is a major health burden in the Asia–Pacific region but consensus on prevention strategies has been lacking. We aimed to critically evaluate for preventing gastric cancer. Methods: A multidisciplinary group developed statements using Delphi approach. Relevant data were presented, quality of evidence, strength recommendation, level graded. Results: Helicobacter pylori infection necessary not sufficient causal factor non‐cardia adenocarcinoma. high...

10.1111/j.1440-1746.2008.05314.x article EN Journal of Gastroenterology and Hepatology 2008-03-01

Abstract Non‐alcoholic fatty liver disease (NAFLD) is the most common disorder in Western industrialized countries, affecting 20–40% of general population. Large population‐based surveys China, Japan, and Korea indicate that prevalence NAFLD now 12% to 24% population subgroups, depending on age, gender, ethnicity, location (urban versus rural). There strong evidence has increased recently parallel with regional trends obesity, type 2 diabetes, metabolic syndrome; further increases are...

10.1111/j.1440-1746.2007.05001.x article EN Journal of Gastroenterology and Hepatology 2007-06-01

<h3>Objective</h3> To develop and validate a clinical risk score predictive of for colorectal advanced neoplasia Asia. <h3>Methods</h3> A prospective, cross-sectional multicentre study was carried out in tertiary hospitals 11 Asian cities. The subjects comprise 2752 asymptomatic patients undergoing screening colonoscopy. From development set 860 colonoscopy, multiple logistic regression applied to identify significant factors defined as invasive carcinoma or adenoma. ORs were utilised...

10.1136/gut.2010.221168 article EN Gut 2011-03-14

Non-variceal upper gastrointestinal bleeding remains an important emergency condition, leading to significant morbidity and mortality. As endoscopic therapy is the ’gold standard' of management, treatment these patients can be considered in three stages: pre-endoscopic treatment, haemostasis post-endoscopic management. Since publication Asia-Pacific consensus on non-variceal (NVUGIB) 7 years ago, there have been advancements clinical management all stages. These include pre-endoscopy risk...

10.1136/gutjnl-2018-316276 article EN cc-by-nc Gut 2018-04-24

<h3>Objective</h3> Since the publication of Asia-Pacific consensus on gastro-oesophageal reflux disease in 2008, there has been further scientific advancement this field. This updated focuses proton pump inhibitor-refractory and Barrett9s oesophagus. <h3>Methods</h3> A steering committee identified three areas to address: (1) burden diagnosis disease; (2) (3) Three working groups formulated draft statements with supporting evidence. Discussions were done via email before a final face-to-face...

10.1136/gutjnl-2016-311715 article EN Gut 2016-06-03

Abstract Background and Aims: Since the publication of Asia‐Pacific GERD consensus in 2004, more data concerning epidemiology management gastroesophageal reflux disease (GERD) have emerged. An evidence based review update was needed. Methods: A multidisciplinary group developed statements using Delphi approach. Relevant were presented, quality evidence, strength recommendation, level graded. Results: is increasing frequency Asia. Risk factors include older age, male sex, race, family...

10.1111/j.1440-1746.2007.05249.x article EN Journal of Gastroenterology and Hepatology 2007-12-13

This study was undertaken to compare the early antiviral activity and viral kinetic profiles of entecavir (ETV) versus adefovir (ADV) in hepatitis B e antigen positive nucleoside-naïve adults with chronic (CHB). Sixty-nine CHB patients baseline HBV DNA 10(8) copies/mL or more were randomized 1:1 open-label treatment 0.5 mg/day 10 for a minimum 52 weeks. The primary efficacy analysis compared mean reduction at week 12 adjusted levels using linear regression. Entecavir superior change from...

10.1002/hep.22658 article EN Hepatology 2008-09-26
Coming Soon ...